The present invention deals with a method for therapeutic or prophylactictreatment of HIV, in particular a prophylacticvaccinal method, comprising at least: administering to a patient a firstantigen comprising the broadly neutralizing epitopesof the Membrane Proximal Ectodomain Region (MPER) of gp41, and administeringto the same patient a second antigen comprisinga modified polypeptide comprising three contiguous segments N, L and Crepresented by the formula N-L-C and comprising :a N-helix region of gp41(N), a C-helix region of gp41(C), and a connectingloop comprising a synthetic linker (L) between the Nand C-helices, the linker replacing amino acids 593-617 of gp41, the numberingscheme being based upon the prototypic isolateHIV-1 HxB2 Clade B strain, said polypeptide comprising the calveolin-1neutralizing and 98.6 D epitopes, but not 2F5 and 4E10epitopes, not the fusion peptide, the polypeptide having a minimal immunogeniccross-reactivity with human interleukin 2.
